← All trials
NCT03264547
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 28, 2017
- Primary completion
- Apr 30, 2022
- Completion date
- Oct 31, 2023
- First posted
- —
- Last posted
- —
- Enrollment
- 480
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Japan Breast Cancer Research GroupLead sponsor
- EisaiCollaborator
- Kanagawa Prefectural Cancer CenterOverall official - principal investigator
- Fukushima Medical UniversityOverall official - principal investigator
- National Hospital Organization Osaka National HospitalOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.